J&J beats Novartis' blockbuster rival in a head-to-head showdown over the psoriasis market
Score a round in the battle of the psoriasis blockbusters for J&J.
The pharma giant heralded a win for their head-to-head study of Tremfya (guselkumab) against Novartis’ dominant rival Cosentyx. Researchers said that 84.5% of the psoriasis patients taking their IL-23 drug hit a PASI90 score at 48 weeks, compared to 70% for the IL-17 drug Cosentyx.
That bodes well for ongoing late-stage studies of their drug in psoriatic arthritis and Crohn’s disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
